Hepatocellular CarcinomaPhase 1NCT05155189
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
A Phase 1 study testing C-CAR031, Lenvatinib and Regorafenib (BAY 73-4506) in people with Hepatocellular Carcinoma, run by Zhejiang University at 2 sites in China.
Trial summary
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hepatocellular Carcinoma
- What is being tested?
- C-CAR031, Lenvatinib and Regorafenib (BAY 73-4506)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 2 sitesChina
- Study dates
- 21 Feb 2022to May 2041
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1.Voluntary participation and able to sign the informed consent form
- 2. Aged 18 to 75 years at screening
- 3. Patients with histologically confirmed hepatocellular carcinoma (HCC) who meet the following requirements: a. Barcelona Clinic Liver Cancer Stage B or C (BCLC B/C) b. Child-Pugh score ≤ 6 c. GPC3 is possibly expressed in tumor tissues
- 4. Patients with relapsed / progressive disease after at least one prior standard systemic therapy for HCC, or ineligible to accept/unable to tolerate the systemic therapies. Standard systemic therapies may include targeted drugs (such as Sorafenib, Lenvatinib, Donafenib, Apatinib), immune checkpoint inhibitors (such as Atezolizumab, Pembrolizumab, Camrelizumab, Sintilimab, Nivolumab, Toripalimab, Tislelizumab) or chemotherapeutic drugs (such as Oxaliplatin and 5-Fu). Subjects in theC-CAR031 plus Lenvatinib group must meet the following criteria: (1)have not received prior Lenvatinib therapy; (2) Progression or intolerance to one prior line of systemic therapy containing both immune checkpoint inhibitors and VEGF/VEGFR- targeted agents. Subjects in the C-CAR031 combination with Regorafenib group must meet the following criteria: (1)have not received prior Regorafenib therapy; (2) Progression or intolerance to one prior line of systemic therapy containing both immune checkpoint inhibitors and VEGF/VEGFR- targeted agents. Subjects in theC-CAR031 plus Durvalumab group must meet the following criteria:(1) Progression or intolerance to one prior line of systemic therapy containing both immune checkpoint inhibitors and VEGF/VEGFR-targeted agents; (2) no prior immune-related toxicity leading to permanent discontinuation of immunotherapy;(3) no history of ≥ Grade 3 immune-related adverse events (irAEs), or any grade immune-related neurological/ocular AEs. (Note: Subjects with ≤ Grade 2 endocrine AEs may enroll if asymptomatic on stable replacement therapy, excluding those: a. requiring non-corticosteroid immunosuppressants, b. experiencing AE recurrence upon immunotherapy rechallenge, c. or using corticosteroids at >10 mg/day prednisone or equivalent.) (4) All AEs associated with prior immunotherapy must have resolved or returned to pre-treatment levels prior to screening; (5) Body weight more than 30 kg.
- 5. At least one measurable target lesion (as per RECIST v1.1)
- 6. WHO/ECOG performance status (PS) score of 0 or 1 point
Show all 13Show fewer
- 7. Expected survival ≥ 12 weeks
- 8. Left ventricular ejection fraction (LVEF) by echocardiography ≥ 45%
- 9. No active pulmonary infection; no known history of pneumonitis requiring steroids; absence of acute onset or progressive pneumonitis at baseline.
- 10. Laboratory tests: a. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L b. Lymphocyte count ≥ 0.4 × 109/L c. Platelet count ≥ 60 × 109/L d. Hemoglobin ≥ 80 g/L e. Total bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN) f. AST and ALT ≤ 5 × ULN g. Serum creatinine ≤ 1.5 × ULN h. Prothrombin time (PT): prolonged PT ≤ 4 s
- 11. Patients without history of HBV infection, or with HBV DNA < 2000 IU/mL (or 10000 copies/mL) at screening who agree to receive anti-virus therapies throughout the study according to the guidelines
- 12. Negative serum or urine pregnancy test results for females of child-bearing age at screening; In addition, they should agree to take effective contraceptive measures throughout the study
- 13. Patients who agree to abstain from drinking throughout the study
Who cannot join
- 1. History of severe allergic or hypersensitivity to DMSO. Subjects with known allergies to the active components of Lenvatinib, Regorafenib, or Durvalumab will be excluded from respective combination treatment groups.
- 2. History of liver transplantation
- 3. History of prior cell therapy
- 4. Tumor volume > 50% of the liver.
- 5. portal stem vein tumor thrombus
- 6. Moderate to severe ascites.
Show all 24Show fewer
- 7. Metastases to bones or central nervous system (CNS), or involved CNS diseasesincluding hepatic encephalopathy, epilepsy, cerebrovascular accidents, etc.
- 8. Receipt of radiotherapy within 6 weeks prior to apheresis
- 9. Receipt of Local therapy (such as surgery, ablation, and intervention) within 4 weeks prior to apheresis or presence of unhealed wounds before apheresis
- 10. Receipt of systemic treatment and failure to meet the minimum requirements for wash-out periods before apheresis: a. Immune checkpointinhibitors: 2 weeks; b. Small molecule target therapy: < 7 days; c. Systemic anti-tumor therapies using experimental anticancer drugs or other Chinese herbal medicines and Chinese patent medicines with unclear mechanisms: 2 weeks; d. Steroids (except inhaled steroids) or other immunomodulators (including interleukins, interferons, and thymosins) of systemic therapeutic dose: 2 weeks; e. Any unresolved toxicity ≥ NCI CTCAE Grade 2 from prior anticancer therapy, except alopecia, vitiligo, and laboratory abnormalities explicitly permitted by the inclusion criteria.
- 11. Other history of primary cancers, excluding:a. Nonmelanoma skin cancer cured by resection (such as basal cell carcinoma) b. Cured carcinoma in situ (such as cervical cancer, bladder cancer, and breast cancer)
- 12. Active hepatitis C virus infection (HCV RNA positive)
- 13. Syphilis infection
- 14. History of active/immunodeficient diseases (including but not limited to HIV, systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, Graves' disease, and hypophysitis; excluding: vitiligo or alopecia, hypothyroidism in patients with stable medical conditions after hormone replacement therapy, any chronic skin conditions that need no systemic treatment, and other diseases judged by the investigator to be of no clinical significance)
- 15. Persistent and active infections (excluding prophylactic anti-infectives)
- 16. Uncontrolled hypertension, diabetes, arrhythmia, and symptomatic congestive heart failure
- 17. Dementia or mental state changes supported by obvious clinical evidence
- 18. Cardiac insufficiency: class III or IV, according to the New York Heart Association (NYHA) functional classifications
- 19. Unstable heart or lung diseases
- 20. Obvious bleeding risks or tendencies
- 21. Females who are pregnant or breastfeeding or expect to be pregnant or breastfeeding during the study
- 22. Other diseases that may add further risks to the subject or interfere with the study results as judged by the investigators
- 23. For combination with Lenvatinib, Regorafenib or Durvalumab, the following will be excluded: a. History of renal disease or nephrotic syndrome; b. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulation, or previous intestinal resection that precludes adequate absorption, distribution, metabolism, or excretion of Lenvatinib or Regorafenib; c. History of ≥ Grade 3 bleeding disorder, vasculitis, or significant gastrointestinal bleeding episodes within 28 days prior to screening; d. History of arterial thromboembolic events (ATEs), including myocardial infarction, cerebrovascular accident, or transient ischemic attack within 6 months prior to screening; e. Serious or non-healing wound, active gastrointestinal ulcer, or bone fracture within 28 days prior to screening; f. Use of full-dose anticoagulants or thrombolytics for non-prophylactic purposes within 10 days prior to screening; g. History of deep vein thrombosis, pulmonary embolism, or any other clinically significant thromboembolism within 3 months prior to screening; h. Presence of symptomatic or uncontrolled hypertension.
- 24. Uncontrolled intermittent severe chronic gastrointestinal disorders associated with diarrhea (excluded from the durvalumab treatment group).
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Recruiting
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003
TingBo Liang, MD, PHD, 086-571-87236688, liangtingbo@zju.edu.cn
- Recruiting
The first affiliated hospital of Zhengzhou University
Zhengzhou
Yanru Qin, 0371-66271157, yanruqin@163.com
About this study
Official title: A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.
Read the detailed description
This study plans to enroll 4-36 patients to assess the safety of C-CAR031. Subjects who meet the eligibility criteria will receive a single dose of C-CAR031 injection, and will be followed up post-treatment for safety monitoring. This study will also enroll 6-36 patients to further explore the treatment modality of combination with Lenvatinib, Regorafenib or Durvalumab at explored safe and effective dose level(s) of C-CAR031 monotherapy in specific eligible advanced HCC patients to provide data support for the phase II study of CAR-T combination therapy. The follow-up period will be 12 months.
- Conditions
- Hepatocellular Carcinoma
- Being tested
- C-CAR031, Lenvatinib, Regorafenib (BAY 73-4506), Durvalumab
- Keywords
- Liver Cancer
- Medical subject headings
- Carcinoma, Hepatocellular, Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
C-CAR031Biological
Targeting GPC3 armored CART cell injection (C-CAR031)
LenvatinibDrug
Tyrosine kinase inhibitors
Regorafenib (BAY 73-4506)Drug
Tyrosine kinase inhibitors
DurvalumabDrug
Immune checkpoint inhibitors, ICIs
| Study group | Role | What they receive |
|---|---|---|
| C-CAR031 | Experimental | Autologous C-CAR031 administered by intravenous (IV) infusion Receives: Biological: C-CAR031 |
| C-CAR031 combined with Lenvatinb | Experimental | Autologous C-CAR031 combination with Lenvatinib Receives: Biological: C-CAR031; Drug: Lenvatinib |
| C-CAR031 combined with Regorafenib | Experimental | Autologous C-CAR031 combination with Regorafenib Receives: Biological: C-CAR031; Drug: Regorafenib (BAY 73-4506) |
| C-CAR031 combined with Durvalumab | Experimental | Autologous C-CAR031 combination with Durvalumab Receives: Biological: C-CAR031; Drug: Durvalumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
TEAEs
treatment emergent adverse events
Measured: start pretreatment to 12 months
AESIs
adverse events of special interest
Measured: start pretreatment to 12 months
Secondary outcomes (11)
objective response rate by RECIST 1.1
objective response rate according to RECIST 1.1
Measured: at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion
disease control rate by RECIST 1.1
disease control rate according to RECIST 1.1
Measured: at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion
duration of response by RECIST 1.1
duration of response according to RECIST 1.1
Measured: at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion
progression-free survival by RECIST 1.1
progression-free survival to RECIST 1.1
Measured: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
objective response rate by mRECIST
objective response rate according to mRECIST
Measured: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
disease control rate by RECIST
disease control rate according to mRECIST
Measured: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
duration of response by mRECIST
duration of response according to mRECIST
Measured: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
progression-free survival by mRECIST
progression-free survival to mRECIST
Measured: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
overall survival
overall survival
Measured: start pretreatment to the date of deaths
6-months overall survival
6-months overall survival
Measured: start pretreatment to 6 months after cell infusion
12-months overall survival
12-months overall survival
Measured: start pretreatment to 12 months after cell infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2021
- Study start21 Feb 2022
- Primary completionMay 2026 (estimated)
- Study completionMay 2041 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- More trials run by Zhejiang UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Four Groups Assignment
- Masking
- None (open label)
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhejiang University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, TingBo Liang, Zhejiang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05155189
- Sponsor's protocol ID
- 0921-028
- Status last verified
- Jan 2026
- First submitted
- 7 Dec 2021
- Last updated
- 21 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma
- ClinicalTrials.gov ID
- NCT05155189
- Acronym / sponsor ID
- 0921-028
- Conditions
- Hepatocellular Carcinoma
- Keywords
- Liver Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Zhejiang UniversityUniversity, hospital or other
- Study start
- 21 Feb 2022 (actual)
- Primary completion
- May 2026 (estimated)
- Study completion
- May 2041 (estimated)
- First posted
- 13 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.
Detailed description
This study plans to enroll 4-36 patients to assess the safety of C-CAR031. Subjects who meet the eligibility criteria will receive a single dose of C-CAR031 injection, and will be followed up post-treatment for safety monitoring. This study will also enroll 6-36 patients to further explore the treatment modality of combination with Lenvatinib, Regorafenib or Durvalumab at explored safe and effective dose level(s) of C-CAR031 monotherapy in specific eligible advanced HCC patients to provide data support for the phase II study of CAR-T combination therapy. The follow-up period will be 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Four Groups Assignment
| Arm | Type | Receives |
|---|---|---|
| C-CAR031 | Experimental | Biological: C-CAR031Autologous C-CAR031 administered by intravenous (IV) infusion |
| C-CAR031 combined with Lenvatinb | Experimental | Biological: C-CAR031, Drug: LenvatinibAutologous C-CAR031 combination with Lenvatinib |
| C-CAR031 combined with Regorafenib | Experimental | Biological: C-CAR031, Drug: Regorafenib (BAY 73-4506)Autologous C-CAR031 combination with Regorafenib |
| C-CAR031 combined with Durvalumab | Experimental | Biological: C-CAR031, Drug: DurvalumabAutologous C-CAR031 combination with Durvalumab |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- 1.Voluntary participation and able to sign the informed consent form
- 2. Aged 18 to 75 years at screening
- 3. Patients with histologically confirmed hepatocellular carcinoma (HCC) who meet the following requirements: a. Barcelona Clinic Liver Cancer Stage B or C (BCLC B/C) b. Child-Pugh score ≤ 6 c. GPC3 is possibly expressed in tumor tissues
- 4. Patients with relapsed / progressive disease after at least one prior standard systemic therapy for HCC, or ineligible to accept/unable to tolerate the systemic therapies. Standard systemic therapies may include targeted drugs (such as Sorafenib, Lenvatinib, Donafenib, Apatinib), immune checkpoint inhibitors (such as Atezolizumab, Pembrolizumab, Camrelizumab, Sintilimab, Nivolumab, Toripalimab, Tislelizumab) or chemotherapeutic drugs (such as Oxaliplatin and 5-Fu). Subjects in theC-CAR031 plus Lenvatinib group must meet the following criteria: (1)have not received prior Lenvatinib therapy; (2) Progression or intolerance to one prior line of systemic therapy containing both immune checkpoint inhibitors and VEGF/VEGFR- targeted agents. Subjects in the C-CAR031 combination with Regorafenib group must meet the following criteria: (1)have not received prior Regorafenib therapy; (2) Progression or intolerance to one prior line of systemic therapy containing both immune checkpoint inhibitors and VEGF/VEGFR- targeted agents. Subjects in theC-CAR031 plus Durvalumab group must meet the following criteria:(1) Progression or intolerance to one prior line of systemic therapy containing both immune checkpoint inhibitors and VEGF/VEGFR-targeted agents; (2) no prior immune-related toxicity leading to permanent discontinuation of immunotherapy;(3) no history of ≥ Grade 3 immune-related adverse events (irAEs), or any grade immune-related neurological/ocular AEs. (Note: Subjects with ≤ Grade 2 endocrine AEs may enroll if asymptomatic on stable replacement therapy, excluding those: a. requiring non-corticosteroid immunosuppressants, b. experiencing AE recurrence upon immunotherapy rechallenge, c. or using corticosteroids at >10 mg/day prednisone or equivalent.) (4) All AEs associated with prior immunotherapy must have resolved or returned to pre-treatment levels prior to screening; (5) Body weight more than 30 kg.
- 5. At least one measurable target lesion (as per RECIST v1.1)
Key exclusion criteria (24 listed)
- 1. History of severe allergic or hypersensitivity to DMSO. Subjects with known allergies to the active components of Lenvatinib, Regorafenib, or Durvalumab will be excluded from respective combination treatment groups.
- 2. History of liver transplantation
- 3. History of prior cell therapy
- 4. Tumor volume > 50% of the liver.
- 5. portal stem vein tumor thrombus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| C-CAR031Targeting GPC3 armored CART cell injection (C-CAR031) | Biological | C-CAR031, C-CAR031 combined with Durvalumab, C-CAR031 combined with Lenvatinb, C-CAR031 combined with Regorafenib |
| LenvatinibTyrosine kinase inhibitors | Drug | C-CAR031 combined with Lenvatinb |
| Regorafenib (BAY 73-4506)Tyrosine kinase inhibitors | Drug | C-CAR031 combined with Regorafenib |
| DurvalumabImmune checkpoint inhibitors, ICIs | Drug | C-CAR031 combined with Durvalumab |
Primary outcome
TEAEs
Time frame: start pretreatment to 12 months
treatment emergent adverse events
AESIs
Time frame: start pretreatment to 12 months
adverse events of special interest
11 secondary outcomes
objective response rate by RECIST 1.1
Time frame: at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion
disease control rate by RECIST 1.1
Time frame: at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion
duration of response by RECIST 1.1
Time frame: at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion
progression-free survival by RECIST 1.1
Time frame: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
objective response rate by mRECIST
Time frame: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
disease control rate by RECIST
Time frame: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
duration of response by mRECIST
Time frame: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
progression-free survival by mRECIST
Time frame: The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.-
overall survival
Time frame: start pretreatment to the date of deaths
6-months overall survival
Time frame: start pretreatment to 6 months after cell infusion
12-months overall survival
Time frame: start pretreatment to 12 months after cell infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Carcinoma
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing C-CAR031, Lenvatinib and Regorafenib (BAY 73-4506) in people with Hepatocellular Carcinoma, run by Zhejiang University at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Qihan Fu (18268173309, ayfuqihan@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TEAEs (time frame: start pretreatment to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.